Literature DB >> 26055231

N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution.

Stephen D Skaper1, Laura Facci, Massimo Barbierato, Morena Zusso, Giuseppe Bruschetta, Daniela Impellizzeri, Salvatore Cuzzocrea, Pietro Giusti.   

Abstract

Inflammation is fundamentally a protective cellular response aimed at removing injurious stimuli and initiating the healing process. However, when prolonged, it can override the bounds of physiological control and becomes destructive. Inflammation is a key element in the pathobiology of chronic pain, neurodegenerative diseases, stroke, spinal cord injury, and neuropsychiatric disorders. Glia, key players in such nervous system disorders, are not only capable of expressing a pro-inflammatory phenotype but respond also to inflammatory signals released from cells of immune origin such as mast cells. Chronic inflammatory processes may be counteracted by a program of resolution that includes the production of lipid mediators endowed with the capacity to switch off inflammation. These naturally occurring lipid signaling molecules include the N-acylethanolamines, N-arachidonoylethanolamine (an endocannabinoid), and its congener N-palmitoylethanolamine (palmitoylethanolamide or PEA). PEA may play a role in maintaining cellular homeostasis when faced with external stressors provoking, for example, inflammation. PEA is efficacious in mast cell-mediated models of neurogenic inflammation and neuropathic pain and is neuroprotective in models of stroke, spinal cord injury, traumatic brain injury, and Parkinson disease. PEA in micronized/ultramicronized form shows superior oral efficacy in inflammatory pain models when compared to naïve PEA. Intriguingly, while PEA has no antioxidant effects per se, its co-ultramicronization with the flavonoid luteolin is more efficacious than either molecule alone. Inhibiting or modulating the enzymatic breakdown of PEA represents a complementary therapeutic approach to treat neuroinflammation. This review is intended to discuss the role of mast cells and glia in neuroinflammation and strategies to modulate their activation based on leveraging natural mechanisms with the capacity for self-defense against inflammation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26055231     DOI: 10.1007/s12035-015-9253-8

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  71 in total

1.  A granular variant of CD63 is a regulator of repeated human mast cell degranulation.

Authors:  Thorsten Schäfer; P Starkl; C Allard; R M Wolf; T Schweighoffer
Journal:  Allergy       Date:  2010-03-20       Impact factor: 13.146

Review 2.  Mast cells as early responders in the regulation of acute blood-brain barrier changes after cerebral ischemia and hemorrhage.

Authors:  Perttu Johannes Lindsberg; Daniel Strbian; Marja-Liisa Karjalainen-Lindsberg
Journal:  J Cereb Blood Flow Metab       Date:  2010-01-20       Impact factor: 6.200

Review 3.  Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease.

Authors:  Marco Prinz; Josef Priller
Journal:  Nat Rev Neurosci       Date:  2014-04-09       Impact factor: 34.870

4.  Chronic stress induces transient spinal neuroinflammation, triggering sensory hypersensitivity and long-lasting anxiety-induced hyperalgesia.

Authors:  Cyril Rivat; Chrystel Becker; Aurélie Blugeot; Brigitte Zeau; Annie Mauborgne; Michel Pohl; Jean-Jacques Benoliel
Journal:  Pain       Date:  2010-06-22       Impact factor: 6.961

5.  Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models.

Authors:  Oscar Sasso; Guillermo Moreno-Sanz; Cataldo Martucci; Natalia Realini; Mauro Dionisi; Luisa Mengatto; Andrea Duranti; Glauco Tarozzo; Giorgio Tarzia; Marco Mor; Rosalia Bertorelli; Angelo Reggiani; Daniele Piomelli
Journal:  Pain       Date:  2012-11-02       Impact factor: 6.961

Review 6.  Peripheral gating of pain signals by endogenous lipid mediators.

Authors:  Daniele Piomelli; Oscar Sasso
Journal:  Nat Neurosci       Date:  2014-01-28       Impact factor: 24.884

7.  Systemic oxidative stress in older patients with mild cognitive impairment or late onset Alzheimer's disease.

Authors:  Carlo Cervellati; Eleonora Cremonini; Cristina Bosi; Stefania Magon; Amedeo Zurlo; Carlo M Bergamini; Giovanni Zuliani
Journal:  Curr Alzheimer Res       Date:  2013-05-01       Impact factor: 3.498

Review 8.  Neuroinflammation and psychiatric illness.

Authors:  Souhel Najjar; Daniel M Pearlman; Kenneth Alper; Amanda Najjar; Orrin Devinsky
Journal:  J Neuroinflammation       Date:  2013-04-01       Impact factor: 8.322

9.  Oxidative stress and psychological disorders.

Authors:  Samina Salim
Journal:  Curr Neuropharmacol       Date:  2014-03       Impact factor: 7.363

10.  Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain.

Authors:  Daniela Impellizzeri; Giuseppe Bruschetta; Marika Cordaro; Rosalia Crupi; Rosalba Siracusa; Emanuela Esposito; Salvatore Cuzzocrea
Journal:  J Neuroinflammation       Date:  2014-08-28       Impact factor: 8.322

View more
  47 in total

1.  Pharmacometabolomic signature links simvastatin therapy and insulin resistance.

Authors:  Mona Elbadawi-Sidhu; Rebecca A Baillie; Hongjie Zhu; Yii-Der Ida Chen; Mark O Goodarzi; Jerome I Rotter; Ronald M Krauss; Oliver Fiehn; Rima Kaddurah-Daouk
Journal:  Metabolomics       Date:  2016-12-23       Impact factor: 4.290

2.  Effect of PEA-OXA on neuropathic pain and functional recovery after sciatic nerve crush.

Authors:  Enrico Gugliandolo; Ramona D'amico; Marika Cordaro; Roberta Fusco; Rosalba Siracusa; Rosalia Crupi; Daniela Impellizzeri; Salvatore Cuzzocrea; Rosanna Di Paola
Journal:  J Neuroinflammation       Date:  2018-09-14       Impact factor: 8.322

3.  Principles of pharmacological research of nutraceuticals.

Authors:  Ruth Andrew; Angelo A Izzo
Journal:  Br J Pharmacol       Date:  2017-06       Impact factor: 8.739

4.  Potential therapeutic targets for intracerebral hemorrhage-associated inflammation: An update.

Authors:  Honglei Ren; Ranran Han; Xuemei Chen; Xi Liu; Jieru Wan; Limin Wang; Xiuli Yang; Jian Wang
Journal:  J Cereb Blood Flow Metab       Date:  2020-05-19       Impact factor: 6.200

Review 5.  The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations.

Authors:  Stefania Petrosino; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2016-09-29       Impact factor: 8.739

Review 6.  On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence.

Authors:  Karen Jaqueline Paredes-Ruiz; Karla Chavira-Ramos; Mario Orozco-Morales; Cimen Karasu; Alexey A Tinkov; Michael Aschner; Abel Santamaría; Ana Laura Colín-González
Journal:  Neurotox Res       Date:  2021-11-06       Impact factor: 3.911

7.  Mast Cells Release Chemokine CCL2 in Response to Parkinsonian Toxin 1-Methyl-4-Phenyl-Pyridinium (MPP(+)).

Authors:  Duraisamy Kempuraj; Ramasamy Thangavel; Ranan Fattal; Sagar Pattani; Evert Yang; Smita Zaheer; Donna A Santillan; Mark K Santillan; Asgar Zaheer
Journal:  Neurochem Res       Date:  2015-12-08       Impact factor: 3.996

8.  Alteration in the Cerebrospinal Fluid Lipidome in Parkinson's Disease: A Post-Mortem Pilot Study.

Authors:  Joaquín Fernández-Irigoyen; Paz Cartas-Cejudo; Marta Iruarrizaga-Lejarreta; Enrique Santamaría
Journal:  Biomedicines       Date:  2021-04-29

Review 9.  Palmitoylethanolamide: A Natural Compound for Health Management.

Authors:  Paul Clayton; Mariko Hill; Nathasha Bogoda; Silma Subah; Ruchitha Venkatesh
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

Review 10.  Mediterranean Diet and Neurodegenerative Diseases: The Neglected Role of Nutrition in the Modulation of the Endocannabinoid System.

Authors:  Federica Armeli; Alessio Bonucci; Elisa Maggi; Alessandro Pinto; Rita Businaro
Journal:  Biomolecules       Date:  2021-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.